Lipfendra (enlicitide decanoate)

Where it stands

Lipfendra (enlicitide decanoate), from Msd, was approved by the US FDA on 2026-07-15 under NDA220848. The records describe it as a new medicine in tablet form. The only milestone on file is this approval, and the source is official.

The records give no therapeutic area and no indication. This analysis therefore cannot say which patients the product is approved for, the approved dose, or any conditions of use. Those details are in the approved prescribing information, which is not part of the records.

The records show no CHMP opinion date, so they contain no EU regulatory activity for this product. The US approval should not be read as implying anything about EU timing or outcome.

Regulatory pathway and designations

The product was reviewed as a New Drug Application (NDA) and carries two designations: New molecular entity and Priority review. In general, an NME designation means the FDA considers the active ingredient not previously approved in the US. Priority review is a review-speed designation, not a statement about the strength of the data.

In general, priority review sets a shorter FDA target for the review clock than standard review. For NMEs this is about six months from the filing date, rather than ten. The records do not give the submission date, the FDA goal date or the length of the review, so the actual review time cannot be stated.

The records do not show whether other expedited programs applied, such as Breakthrough Therapy, Fast Track or accelerated approval. They also do not show whether the approval carries postmarketing requirements. None of these should be assumed.

Safety and pharmacovigilance

The records contain no safety information, such as warnings, adverse reaction data, a boxed warning, a REMS or postmarketing commitments, so no safety assessment can be made from them.

What to watch

The first step is to read the approved label and the FDA approval documents. These will confirm the indication, population, dosing, warnings and any postmarketing requirements or commitments. The records do not include any of this.

Beyond that, the records do not show ex-US filings or regulatory milestones, including any EU submission, validation or CHMP opinion. Those would need to be confirmed from company or agency sources.

Post-approval activity, such as label updates, safety communications and any required postmarketing studies, will become visible through FDA and company disclosures. Nothing on these is in the records yet.